BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25078248)

  • 1. Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.
    Luetkens T; Kobold S; Cao Y; Ristic M; Schilling G; Tams S; Bartels BM; Templin J; Bartels K; Hildebrandt Y; Yousef S; Marx A; Haag F; Bokemeyer C; Kröger N; Atanackovic D
    Cancer Immunol Immunother; 2014 Nov; 63(11):1151-62. PubMed ID: 25078248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.
    Maio M; Coral S; Sigalotti L; Elisei R; Romei C; Rossi G; Cortini E; Colizzi F; Fenzi G; Altomonte M; Pinchera A; Vitale M
    J Clin Endocrinol Metab; 2003 Feb; 88(2):748-54. PubMed ID: 12574209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.
    Atanackovic D; Arfsten J; Cao Y; Gnjatic S; Schnieders F; Bartels K; Schilling G; Faltz C; Wolschke C; Dierlamm J; Ritter G; Eiermann T; Hossfeld DK; Zander AR; Jungbluth AA; Old LJ; Bokemeyer C; Kröger N
    Blood; 2007 Feb; 109(3):1103-12. PubMed ID: 17023585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma.
    Lu Y; Wu LQ; Lü ZH; Wang XJ; Yang JY
    Chin Med J (Engl); 2007 Jun; 120(12):1042-6. PubMed ID: 17637219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of CT antigen expression and humoral immunogenicity of NY-ESO-1 protein in gastric carcinoma].
    Wu XJ; Wang Y; Ji JF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):252-6. PubMed ID: 15968313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
    Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
    Stockert E; Jäger E; Chen YT; Scanlan MJ; Gout I; Karbach J; Arand M; Knuth A; Old LJ
    J Exp Med; 1998 Apr; 187(8):1349-54. PubMed ID: 9547346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.
    Taylor BJ; Reiman T; Pittman JA; Keats JJ; de Bruijn DR; Mant MJ; Belch AR; Pilarski LM
    J Immunother; 2005; 28(6):564-75. PubMed ID: 16224274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
    Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
    PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration.
    Kim SH; Lee S; Lee CH; Lee MK; Kim YD; Shin DH; Choi KU; Kim JY; Park DY; Sol MY
    Lung; 2009; 187(6):401-11. PubMed ID: 19795170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
    Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
    Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
    Schuberth PC; Jakka G; Jensen SM; Wadle A; Gautschi F; Haley D; Haile S; Mischo A; Held G; Thiel M; Tinguely M; Bifulco CB; Fox BA; Renner C; Petrausch U
    Gene Ther; 2013 Apr; 20(4):386-95. PubMed ID: 22739387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
    Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
    Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
    Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
    Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
    Stadtmauer EA; Faitg TH; Lowther DE; Badros AZ; Chagin K; Dengel K; Iyengar M; Melchiori L; Navenot JM; Norry E; Trivedi T; Wang R; Binder GK; Amado R; Rapoport AP
    Blood Adv; 2019 Jul; 3(13):2022-2034. PubMed ID: 31289029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
    Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
    Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
    Karbach J; Pauligk C; Bender A; Gnjatic S; Franzmann K; Wahle C; Jäger D; Knuth A; Old LJ; Jäger E
    Int J Cancer; 2006 Feb; 118(3):668-74. PubMed ID: 16152624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma.
    Bricard G; Bouzourene H; Martinet O; Rimoldi D; Halkic N; Gillet M; Chaubert P; Macdonald HR; Romero P; Cerottini JC; Speiser DE
    J Immunol; 2005 Feb; 174(3):1709-16. PubMed ID: 15661935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
    Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
    Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.